ProShare Advisors
STLN icon

ProShare Advisors’s Starling Oncology STLN Stock Holding History

ProShare Advisors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-10,026
Closed -$54.4K – 1951
2026
Q2 		$54.4K Sell
10,026
-1,535
-13% -$6.45K ﹤0.01% 1835
2026
Q1 		$35.5K Sell
11,561
-908
-7% -$2.78K ﹤0.01% 1810
2025
Q4 		$44.4K Buy
12,469
+2,208
+22% +$8.19K ﹤0.01% 1969
2025
Q3 		$35.8K Sell
10,261
-1,843
-15% -$6.32K ﹤0.01% 1960
2025
Q2 		$24.8K Buy
+12,104
New +$30.3K ﹤0.01% 2055

Other funds holding STLN

Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Kingswood Wealth Advisors
Kingswood Wealth Advisors San Diego, California $2.6B AUM 27.46% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
T3 Companies
T3 Companies New York $103M AUM 54.73% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Berkshire Money Management
Berkshire Money Management Dalton, Massachusetts $1.16B AUM 13.8% 1-Year Est. Return
Granite Investment Partners
Granite Investment Partners El Segundo, California $1.84B AUM 35.93% 1-Year Est. Return
Pekin Hardy Strauss
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 25.53% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

ProShare Advisors's STLN Position: Q3 2026 in Review

ProShare Advisors sold out of Starling Oncology (STLN) in Q3 2026, closing a stake of 10,026 shares — an estimated $54.4K sold.

ProShare Advisors first reported a position in STLN in Q2 2025 and held it in 5 quarters. The position peaked at $54.4K in Q2 2026. 26 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

  • ProShare Advisors reported no remaining Starling Oncology position as of Q3 2026 after selling out during the quarter.
  • ProShare Advisors sold 10,026 Starling Oncology shares in Q3 2026, an estimated $54.4K.
  • ProShare Advisors first reported a position in Starling Oncology in Q2 2025 and held it in 5 quarters.
  • ProShare Advisors's Starling Oncology position peaked at $54.4K in Q2 2026.
  • 26 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on ProShare Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.